Denali Therapeutics Inc.Financials
|
|
Historical Financials
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | - | - | 330,531,000 | 108,463,000 | 48,661,000 | 335,659,000 | 26,678,000 | 129,160,000 | - | - | |
| Gross Profit Margin (%) | - | - | - | - | - | - | - | - | - | - | |
| R&D Expense | 418,778,000 | 396,440,000 | 423,876,000 | 358,732,000 | 265,353,000 | 212,615,000 | 193,382,000 | 143,183,000 | 74,460,000 | 75,702,000 |
Sign up to view full financial statements
Create a free CapEdge account to access balance sheet, cash flow, and complete historical data.
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SG&A Expense | |||||||||||
| Total Operating Expenses | |||||||||||
| Operating Income or Loss | |||||||||||
| Operating Margin (%) | |||||||||||
| EBITDA | |||||||||||
| Non-Operating Income/Expense | |||||||||||
| Income Tax Expense | |||||||||||
| Net Income | |||||||||||
| Net Profit Margin (%) | |||||||||||
| Basic EPS | |||||||||||
| Diluted EPS | |||||||||||
| Basic Average Shares | |||||||||||
| Diluted Average Shares |
All numbers in thousands. Financial statements are in beta and sourced from EDGAR XBRL filings. Read the caveats.